Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00083489" target="_blank" >RIV/00216224:14110/15:00083489 - isvavai.cz</a>
Alternative codes found
RIV/00159816:_____/15:00063165
Result on the web
<a href="http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract" target="_blank" >http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.amjcard.2015.05.022" target="_blank" >10.1016/j.amjcard.2015.05.022</a>

Result language
angličtina
Original language name
Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy
Original language description
The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment- phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by thepatient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 +/- 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the useof PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Project
<a href="/en/project/ED1.100%2F02%2F0123" target="_blank" >ED1.100/02/0123: St. Anne´s University Hospital Brno - International Clinical Research Center (FNUSA-ICRC)</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)